Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06691217 · ClinicalTrials.gov registry record · Phase 2
Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT06691217: Recruiting Phase 2 study, sponsored by Massachusetts General Hospital.
NCT06691217 is a Phase 2 study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06691217, a Phase 2 study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET2.
Interventions
- DRUG CANAKINUMAB (ILARIS®)
- DRUG Saline (NaCl 0,9 %) (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-03-24 |
| Est. Completion | 2030-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06691217
The ClinicalTrials.gov registry entry for NCT06691217 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CANAKINUMAB (ILARIS®) is the first listed.
NCT06691217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06691217 about?
NCT06691217 is a clinical study titled "Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis". The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET...
What is the current status of trial NCT06691217?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-03-24. Estimated completion is 2030-04-01.
What interventions are being tested in trial NCT06691217?
The interventions under investigation include: CANAKINUMAB (ILARIS®) (DRUG), Saline (NaCl 0,9 %) (placebo) (DRUG).
Who is sponsoring clinical trial NCT06691217?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.